index	sentence
0	Four additional @Gene$ mutations (@Mutation$ (1 out of 106 tumours), Lys117Asn (1 out of 106), Ala146Thr (7 out of 106) and Arg164Gln (1 out of 106)) were identified
1	Four additional @Gene$ mutations (Leu19Phe (1 out of 106 tumours), @Mutation$ (1 out of 106), Ala146Thr (7 out of 106) and Arg164Gln (1 out of 106)) were identified
2	Four additional @Gene$ mutations (Leu19Phe (1 out of 106 tumours), Lys117Asn (1 out of 106), @Mutation$ (7 out of 106) and Arg164Gln (1 out of 106)) were identified
3	Four additional @Gene$ mutations (Leu19Phe (1 out of 106 tumours), Lys117Asn (1 out of 106), Ala146Thr (7 out of 106) and @Mutation$ (1 out of 106)) were identified
4	@Mutation$ and Ala146Thr had phenotypes similar to the hotspot mutations, whereas Leu19Phe had an attenuated phenotype and the Arg164Gln mutation was phenotypically equivalent to wt @Gene$
5	Lys117Asn and @Mutation$ had phenotypes similar to the hotspot mutations, whereas Leu19Phe had an attenuated phenotype and the Arg164Gln mutation was phenotypically equivalent to wt @Gene$
6	Lys117Asn and Ala146Thr had phenotypes similar to the hotspot mutations, whereas @Mutation$ had an attenuated phenotype and the Arg164Gln mutation was phenotypically equivalent to wt @Gene$
7	Lys117Asn and Ala146Thr had phenotypes similar to the hotspot mutations, whereas Leu19Phe had an attenuated phenotype and the @Mutation$ mutation was phenotypically equivalent to wt @Gene$
8	Ras proteins regulate signal transduction by activating a number of downstream effector proteins, including the cytoplasmic @Mutation$@Gene$ (Figure 1)
9	The most common @Gene$ mutation is a @Mutation$ transversion, resulting in a valine to glutamic acid substitution (V600E), present in approximately 90% of B-Raf mutant tumours (Davies et al, 2002), which results in a 500-fold increase in in vitro kinase activity and the induction of cell proliferation and transformation (Wan et al, 2004)
10	The most common @Gene$ mutation is a T to A transversion, resulting in a @Mutation$ substitution (V600E), present in approximately 90% of B-Raf mutant tumours (Davies et al, 2002), which results in a 500-fold increase in in vitro kinase activity and the induction of cell proliferation and transformation (Wan et al, 2004)
11	The most common @Gene$ mutation is a T to A transversion, resulting in a valine to glutamic acid substitution (@Mutation$), present in approximately 90% of B-Raf mutant tumours (Davies et al, 2002), which results in a 500-fold increase in in vitro kinase activity and the induction of cell proliferation and transformation (Wan et al, 2004)
12	The most common B-Raf mutation is a @Mutation$ transversion, resulting in a valine to glutamic acid substitution (V600E), present in approximately 90% of @Gene$ mutant tumours (Davies et al, 2002), which results in a 500-fold increase in in vitro kinase activity and the induction of cell proliferation and transformation (Wan et al, 2004)
13	The most common B-Raf mutation is a T to A transversion, resulting in a @Mutation$ substitution (V600E), present in approximately 90% of @Gene$ mutant tumours (Davies et al, 2002), which results in a 500-fold increase in in vitro kinase activity and the induction of cell proliferation and transformation (Wan et al, 2004)
14	The most common B-Raf mutation is a T to A transversion, resulting in a valine to glutamic acid substitution (@Mutation$), present in approximately 90% of @Gene$ mutant tumours (Davies et al, 2002), which results in a 500-fold increase in in vitro kinase activity and the induction of cell proliferation and transformation (Wan et al, 2004)
15	Site-directed mutagenesis (SDM) was carried out on the pEFHA wt @Gene$ plasmid using the QuikChange II SDM kit (Agilent, South Queensferry, Edinburgh, UK) according to the manufacturer's instructions to generate the following K-Ras mutations: @Mutation$, G12D, G13D, Q61H, L19F, K117N, A146T and R164Q, using the oligonucleotide primers described in Table 1.
16	Site-directed mutagenesis (SDM) was carried out on the pEFHA wt @Gene$ plasmid using the QuikChange II SDM kit (Agilent, South Queensferry, Edinburgh, UK) according to the manufacturer's instructions to generate the following K-Ras mutations: G12V, @Mutation$, G13D, Q61H, L19F, K117N, A146T and R164Q, using the oligonucleotide primers described in Table 1.
17	Site-directed mutagenesis (SDM) was carried out on the pEFHA wt @Gene$ plasmid using the QuikChange II SDM kit (Agilent, South Queensferry, Edinburgh, UK) according to the manufacturer's instructions to generate the following K-Ras mutations: G12V, G12D, @Mutation$, Q61H, L19F, K117N, A146T and R164Q, using the oligonucleotide primers described in Table 1.
18	Site-directed mutagenesis (SDM) was carried out on the pEFHA wt @Gene$ plasmid using the QuikChange II SDM kit (Agilent, South Queensferry, Edinburgh, UK) according to the manufacturer's instructions to generate the following K-Ras mutations: G12V, G12D, G13D, @Mutation$, L19F, K117N, A146T and R164Q, using the oligonucleotide primers described in Table 1.
19	Site-directed mutagenesis (SDM) was carried out on the pEFHA wt @Gene$ plasmid using the QuikChange II SDM kit (Agilent, South Queensferry, Edinburgh, UK) according to the manufacturer's instructions to generate the following K-Ras mutations: G12V, G12D, G13D, Q61H, @Mutation$, K117N, A146T and R164Q, using the oligonucleotide primers described in Table 1.
20	Site-directed mutagenesis (SDM) was carried out on the pEFHA wt @Gene$ plasmid using the QuikChange II SDM kit (Agilent, South Queensferry, Edinburgh, UK) according to the manufacturer's instructions to generate the following K-Ras mutations: G12V, G12D, G13D, Q61H, L19F, @Mutation$, A146T and R164Q, using the oligonucleotide primers described in Table 1.
21	Site-directed mutagenesis (SDM) was carried out on the pEFHA wt @Gene$ plasmid using the QuikChange II SDM kit (Agilent, South Queensferry, Edinburgh, UK) according to the manufacturer's instructions to generate the following K-Ras mutations: G12V, G12D, G13D, Q61H, L19F, K117N, @Mutation$ and R164Q, using the oligonucleotide primers described in Table 1.
22	Site-directed mutagenesis (SDM) was carried out on the pEFHA wt @Gene$ plasmid using the QuikChange II SDM kit (Agilent, South Queensferry, Edinburgh, UK) according to the manufacturer's instructions to generate the following K-Ras mutations: G12V, G12D, G13D, Q61H, L19F, K117N, A146T and @Mutation$, using the oligonucleotide primers described in Table 1.
23	Site-directed mutagenesis (SDM) was carried out on the pEFHA wt K-Ras plasmid using the QuikChange II SDM kit (Agilent, South Queensferry, Edinburgh, UK) according to the manufacturer's instructions to generate the following @Gene$ mutations: @Mutation$, G12D, G13D, Q61H, L19F, K117N, A146T and R164Q, using the oligonucleotide primers described in Table 1.
24	Site-directed mutagenesis (SDM) was carried out on the pEFHA wt K-Ras plasmid using the QuikChange II SDM kit (Agilent, South Queensferry, Edinburgh, UK) according to the manufacturer's instructions to generate the following @Gene$ mutations: G12V, @Mutation$, G13D, Q61H, L19F, K117N, A146T and R164Q, using the oligonucleotide primers described in Table 1.
25	Site-directed mutagenesis (SDM) was carried out on the pEFHA wt K-Ras plasmid using the QuikChange II SDM kit (Agilent, South Queensferry, Edinburgh, UK) according to the manufacturer's instructions to generate the following @Gene$ mutations: G12V, G12D, @Mutation$, Q61H, L19F, K117N, A146T and R164Q, using the oligonucleotide primers described in Table 1.
26	Site-directed mutagenesis (SDM) was carried out on the pEFHA wt K-Ras plasmid using the QuikChange II SDM kit (Agilent, South Queensferry, Edinburgh, UK) according to the manufacturer's instructions to generate the following @Gene$ mutations: G12V, G12D, G13D, @Mutation$, L19F, K117N, A146T and R164Q, using the oligonucleotide primers described in Table 1.
27	Site-directed mutagenesis (SDM) was carried out on the pEFHA wt K-Ras plasmid using the QuikChange II SDM kit (Agilent, South Queensferry, Edinburgh, UK) according to the manufacturer's instructions to generate the following @Gene$ mutations: G12V, G12D, G13D, Q61H, @Mutation$, K117N, A146T and R164Q, using the oligonucleotide primers described in Table 1.
28	Site-directed mutagenesis (SDM) was carried out on the pEFHA wt K-Ras plasmid using the QuikChange II SDM kit (Agilent, South Queensferry, Edinburgh, UK) according to the manufacturer's instructions to generate the following @Gene$ mutations: G12V, G12D, G13D, Q61H, L19F, @Mutation$, A146T and R164Q, using the oligonucleotide primers described in Table 1.
29	Site-directed mutagenesis (SDM) was carried out on the pEFHA wt K-Ras plasmid using the QuikChange II SDM kit (Agilent, South Queensferry, Edinburgh, UK) according to the manufacturer's instructions to generate the following @Gene$ mutations: G12V, G12D, G13D, Q61H, L19F, K117N, @Mutation$ and R164Q, using the oligonucleotide primers described in Table 1.
30	Site-directed mutagenesis (SDM) was carried out on the pEFHA wt K-Ras plasmid using the QuikChange II SDM kit (Agilent, South Queensferry, Edinburgh, UK) according to the manufacturer's instructions to generate the following @Gene$ mutations: G12V, G12D, G13D, Q61H, L19F, K117N, A146T and @Mutation$, using the oligonucleotide primers described in Table 1.
31	NIH3T3 cells were seeded at 2.5 x 105 cells in 35 mm culture dishes and allowed to adhere overnight before transfection with 250 ng of either pEF.6, pEFHA (wt @Gene$) or plasmids containing one of the following K-Ras mutants: @Mutation$, G12D, G13D, Q61H, L19F, K117N, A146T or R164Q
32	NIH3T3 cells were seeded at 2.5 x 105 cells in 35 mm culture dishes and allowed to adhere overnight before transfection with 250 ng of either pEF.6, pEFHA (wt @Gene$) or plasmids containing one of the following K-Ras mutants: G12V, @Mutation$, G13D, Q61H, L19F, K117N, A146T or R164Q
33	NIH3T3 cells were seeded at 2.5 x 105 cells in 35 mm culture dishes and allowed to adhere overnight before transfection with 250 ng of either pEF.6, pEFHA (wt @Gene$) or plasmids containing one of the following K-Ras mutants: G12V, G12D, @Mutation$, Q61H, L19F, K117N, A146T or R164Q
34	NIH3T3 cells were seeded at 2.5 x 105 cells in 35 mm culture dishes and allowed to adhere overnight before transfection with 250 ng of either pEF.6, pEFHA (wt @Gene$) or plasmids containing one of the following K-Ras mutants: G12V, G12D, G13D, @Mutation$, L19F, K117N, A146T or R164Q
35	NIH3T3 cells were seeded at 2.5 x 105 cells in 35 mm culture dishes and allowed to adhere overnight before transfection with 250 ng of either pEF.6, pEFHA (wt @Gene$) or plasmids containing one of the following K-Ras mutants: G12V, G12D, G13D, Q61H, @Mutation$, K117N, A146T or R164Q
36	NIH3T3 cells were seeded at 2.5 x 105 cells in 35 mm culture dishes and allowed to adhere overnight before transfection with 250 ng of either pEF.6, pEFHA (wt @Gene$) or plasmids containing one of the following K-Ras mutants: G12V, G12D, G13D, Q61H, L19F, @Mutation$, A146T or R164Q
37	NIH3T3 cells were seeded at 2.5 x 105 cells in 35 mm culture dishes and allowed to adhere overnight before transfection with 250 ng of either pEF.6, pEFHA (wt @Gene$) or plasmids containing one of the following K-Ras mutants: G12V, G12D, G13D, Q61H, L19F, K117N, @Mutation$ or R164Q
38	NIH3T3 cells were seeded at 2.5 x 105 cells in 35 mm culture dishes and allowed to adhere overnight before transfection with 250 ng of either pEF.6, pEFHA (wt @Gene$) or plasmids containing one of the following K-Ras mutants: G12V, G12D, G13D, Q61H, L19F, K117N, A146T or @Mutation$
39	NIH3T3 cells were seeded at 2.5 x 105 cells in 35 mm culture dishes and allowed to adhere overnight before transfection with 250 ng of either pEF.6, pEFHA (wt K-Ras) or plasmids containing one of the following @Gene$ mutants: @Mutation$, G12D, G13D, Q61H, L19F, K117N, A146T or R164Q
40	NIH3T3 cells were seeded at 2.5 x 105 cells in 35 mm culture dishes and allowed to adhere overnight before transfection with 250 ng of either pEF.6, pEFHA (wt K-Ras) or plasmids containing one of the following @Gene$ mutants: G12V, @Mutation$, G13D, Q61H, L19F, K117N, A146T or R164Q
41	NIH3T3 cells were seeded at 2.5 x 105 cells in 35 mm culture dishes and allowed to adhere overnight before transfection with 250 ng of either pEF.6, pEFHA (wt K-Ras) or plasmids containing one of the following @Gene$ mutants: G12V, G12D, @Mutation$, Q61H, L19F, K117N, A146T or R164Q
42	NIH3T3 cells were seeded at 2.5 x 105 cells in 35 mm culture dishes and allowed to adhere overnight before transfection with 250 ng of either pEF.6, pEFHA (wt K-Ras) or plasmids containing one of the following @Gene$ mutants: G12V, G12D, G13D, @Mutation$, L19F, K117N, A146T or R164Q
43	NIH3T3 cells were seeded at 2.5 x 105 cells in 35 mm culture dishes and allowed to adhere overnight before transfection with 250 ng of either pEF.6, pEFHA (wt K-Ras) or plasmids containing one of the following @Gene$ mutants: G12V, G12D, G13D, Q61H, @Mutation$, K117N, A146T or R164Q
44	NIH3T3 cells were seeded at 2.5 x 105 cells in 35 mm culture dishes and allowed to adhere overnight before transfection with 250 ng of either pEF.6, pEFHA (wt K-Ras) or plasmids containing one of the following @Gene$ mutants: G12V, G12D, G13D, Q61H, L19F, @Mutation$, A146T or R164Q
45	NIH3T3 cells were seeded at 2.5 x 105 cells in 35 mm culture dishes and allowed to adhere overnight before transfection with 250 ng of either pEF.6, pEFHA (wt K-Ras) or plasmids containing one of the following @Gene$ mutants: G12V, G12D, G13D, Q61H, L19F, K117N, @Mutation$ or R164Q
46	NIH3T3 cells were seeded at 2.5 x 105 cells in 35 mm culture dishes and allowed to adhere overnight before transfection with 250 ng of either pEF.6, pEFHA (wt K-Ras) or plasmids containing one of the following @Gene$ mutants: G12V, G12D, G13D, Q61H, L19F, K117N, A146T or @Mutation$
47	500 mug of cell lysate from each sample was incubated with 10 mug of @Gene$ RBD agarose at 4 @Mutation$ min with gentle rocking
48	NIH3T3 cells were plated at 2.5 x 105 cells per well in a 6-well plate and, following overnight attachment, transfected with 250 ng of pEF, wt @Gene$ or one of the K-Ras mutants: @Mutation$, G12D, G12C, G13D, Q61H, L19F, K117N, A146T and R164Q
49	NIH3T3 cells were plated at 2.5 x 105 cells per well in a 6-well plate and, following overnight attachment, transfected with 250 ng of pEF, wt @Gene$ or one of the K-Ras mutants: G12V, @Mutation$, G12C, G13D, Q61H, L19F, K117N, A146T and R164Q
50	NIH3T3 cells were plated at 2.5 x 105 cells per well in a 6-well plate and, following overnight attachment, transfected with 250 ng of pEF, wt @Gene$ or one of the K-Ras mutants: G12V, G12D, @Mutation$, G13D, Q61H, L19F, K117N, A146T and R164Q
51	NIH3T3 cells were plated at 2.5 x 105 cells per well in a 6-well plate and, following overnight attachment, transfected with 250 ng of pEF, wt @Gene$ or one of the K-Ras mutants: G12V, G12D, G12C, @Mutation$, Q61H, L19F, K117N, A146T and R164Q
52	NIH3T3 cells were plated at 2.5 x 105 cells per well in a 6-well plate and, following overnight attachment, transfected with 250 ng of pEF, wt @Gene$ or one of the K-Ras mutants: G12V, G12D, G12C, G13D, @Mutation$, L19F, K117N, A146T and R164Q
53	NIH3T3 cells were plated at 2.5 x 105 cells per well in a 6-well plate and, following overnight attachment, transfected with 250 ng of pEF, wt @Gene$ or one of the K-Ras mutants: G12V, G12D, G12C, G13D, Q61H, @Mutation$, K117N, A146T and R164Q
54	NIH3T3 cells were plated at 2.5 x 105 cells per well in a 6-well plate and, following overnight attachment, transfected with 250 ng of pEF, wt @Gene$ or one of the K-Ras mutants: G12V, G12D, G12C, G13D, Q61H, L19F, @Mutation$, A146T and R164Q
55	NIH3T3 cells were plated at 2.5 x 105 cells per well in a 6-well plate and, following overnight attachment, transfected with 250 ng of pEF, wt @Gene$ or one of the K-Ras mutants: G12V, G12D, G12C, G13D, Q61H, L19F, K117N, @Mutation$ and R164Q
56	NIH3T3 cells were plated at 2.5 x 105 cells per well in a 6-well plate and, following overnight attachment, transfected with 250 ng of pEF, wt @Gene$ or one of the K-Ras mutants: G12V, G12D, G12C, G13D, Q61H, L19F, K117N, A146T and @Mutation$
57	NIH3T3 cells were plated at 2.5 x 105 cells per well in a 6-well plate and, following overnight attachment, transfected with 250 ng of pEF, wt K-Ras or one of the @Gene$ mutants: @Mutation$, G12D, G12C, G13D, Q61H, L19F, K117N, A146T and R164Q
58	NIH3T3 cells were plated at 2.5 x 105 cells per well in a 6-well plate and, following overnight attachment, transfected with 250 ng of pEF, wt K-Ras or one of the @Gene$ mutants: G12V, @Mutation$, G12C, G13D, Q61H, L19F, K117N, A146T and R164Q
59	NIH3T3 cells were plated at 2.5 x 105 cells per well in a 6-well plate and, following overnight attachment, transfected with 250 ng of pEF, wt K-Ras or one of the @Gene$ mutants: G12V, G12D, @Mutation$, G13D, Q61H, L19F, K117N, A146T and R164Q
60	NIH3T3 cells were plated at 2.5 x 105 cells per well in a 6-well plate and, following overnight attachment, transfected with 250 ng of pEF, wt K-Ras or one of the @Gene$ mutants: G12V, G12D, G12C, @Mutation$, Q61H, L19F, K117N, A146T and R164Q
61	NIH3T3 cells were plated at 2.5 x 105 cells per well in a 6-well plate and, following overnight attachment, transfected with 250 ng of pEF, wt K-Ras or one of the @Gene$ mutants: G12V, G12D, G12C, G13D, @Mutation$, L19F, K117N, A146T and R164Q
62	NIH3T3 cells were plated at 2.5 x 105 cells per well in a 6-well plate and, following overnight attachment, transfected with 250 ng of pEF, wt K-Ras or one of the @Gene$ mutants: G12V, G12D, G12C, G13D, Q61H, @Mutation$, K117N, A146T and R164Q
63	NIH3T3 cells were plated at 2.5 x 105 cells per well in a 6-well plate and, following overnight attachment, transfected with 250 ng of pEF, wt K-Ras or one of the @Gene$ mutants: G12V, G12D, G12C, G13D, Q61H, L19F, @Mutation$, A146T and R164Q
64	NIH3T3 cells were plated at 2.5 x 105 cells per well in a 6-well plate and, following overnight attachment, transfected with 250 ng of pEF, wt K-Ras or one of the @Gene$ mutants: G12V, G12D, G12C, G13D, Q61H, L19F, K117N, @Mutation$ and R164Q
65	NIH3T3 cells were plated at 2.5 x 105 cells per well in a 6-well plate and, following overnight attachment, transfected with 250 ng of pEF, wt K-Ras or one of the @Gene$ mutants: G12V, G12D, G12C, G13D, Q61H, L19F, K117N, A146T and @Mutation$
66	Meanwhile, 1 mul chromosome 12p BAC @Gene$-707G18 (Red) (BlueGnome), 1 mul chromosome 12q BAC RP11-89H19 (Green) (BlueGnome) and 9 mul LSI-WCP hybridisation buffer (Vysis) was mixed together for each slide and pipetted onto a 22 x 22 mm coverslip which was placed onto a region of the slide containing tumour tissue and placed onto a heat block at 75 @Mutation$ min to co-denature the probes and tumour tissue
67	Meanwhile, 1 mul chromosome 12p BAC RP11-707G18 (Red) (BlueGnome), 1 mul chromosome 12q BAC @Gene$-89H19 (Green) (BlueGnome) and 9 mul LSI-WCP hybridisation buffer (Vysis) was mixed together for each slide and pipetted onto a 22 x 22 mm coverslip which was placed onto a region of the slide containing tumour tissue and placed onto a heat block at 75 @Mutation$ min to co-denature the probes and tumour tissue
68	Mutations at codon 19 (@Mutation$, Leu19Phe) and in @Gene$ (V600E) were found in single tumours (Table 2).
69	Mutations at codon 19 (G57T, @Mutation$) and in @Gene$ (V600E) were found in single tumours (Table 2).
70	Mutations at codon 19 (G57T, Leu19Phe) and in @Gene$ (@Mutation$) were found in single tumours (Table 2).
71	Together, these @Gene$ mutations and the B-Raf @Mutation$ mutation increase overall Ras pathway mutation frequency from 27.4 to 37.8%
72	Together, these K-Ras mutations and the @Gene$ @Mutation$ mutation increase overall Ras pathway mutation frequency from 27.4 to 37.8%
73	To compare the transformation potential of the @Gene$ mutants, therefore, NIH3T3 cells were transiently transfected with plasmids expressing wt K-Ras and the K-Ras mutations @Mutation$, G12D, G13D, Q61H, L19F, K117N, A146T and R164Q
74	To compare the transformation potential of the @Gene$ mutants, therefore, NIH3T3 cells were transiently transfected with plasmids expressing wt K-Ras and the K-Ras mutations G12V, @Mutation$, G13D, Q61H, L19F, K117N, A146T and R164Q
75	To compare the transformation potential of the @Gene$ mutants, therefore, NIH3T3 cells were transiently transfected with plasmids expressing wt K-Ras and the K-Ras mutations G12V, G12D, @Mutation$, Q61H, L19F, K117N, A146T and R164Q
76	To compare the transformation potential of the @Gene$ mutants, therefore, NIH3T3 cells were transiently transfected with plasmids expressing wt K-Ras and the K-Ras mutations G12V, G12D, G13D, @Mutation$, L19F, K117N, A146T and R164Q
77	To compare the transformation potential of the @Gene$ mutants, therefore, NIH3T3 cells were transiently transfected with plasmids expressing wt K-Ras and the K-Ras mutations G12V, G12D, G13D, Q61H, @Mutation$, K117N, A146T and R164Q
78	To compare the transformation potential of the @Gene$ mutants, therefore, NIH3T3 cells were transiently transfected with plasmids expressing wt K-Ras and the K-Ras mutations G12V, G12D, G13D, Q61H, L19F, @Mutation$, A146T and R164Q
79	To compare the transformation potential of the @Gene$ mutants, therefore, NIH3T3 cells were transiently transfected with plasmids expressing wt K-Ras and the K-Ras mutations G12V, G12D, G13D, Q61H, L19F, K117N, @Mutation$ and R164Q
80	To compare the transformation potential of the @Gene$ mutants, therefore, NIH3T3 cells were transiently transfected with plasmids expressing wt K-Ras and the K-Ras mutations G12V, G12D, G13D, Q61H, L19F, K117N, A146T and @Mutation$
81	To compare the transformation potential of the K-Ras mutants, therefore, NIH3T3 cells were transiently transfected with plasmids expressing wt @Gene$ and the K-Ras mutations @Mutation$, G12D, G13D, Q61H, L19F, K117N, A146T and R164Q
82	To compare the transformation potential of the K-Ras mutants, therefore, NIH3T3 cells were transiently transfected with plasmids expressing wt @Gene$ and the K-Ras mutations G12V, @Mutation$, G13D, Q61H, L19F, K117N, A146T and R164Q
83	To compare the transformation potential of the K-Ras mutants, therefore, NIH3T3 cells were transiently transfected with plasmids expressing wt @Gene$ and the K-Ras mutations G12V, G12D, @Mutation$, Q61H, L19F, K117N, A146T and R164Q
84	To compare the transformation potential of the K-Ras mutants, therefore, NIH3T3 cells were transiently transfected with plasmids expressing wt @Gene$ and the K-Ras mutations G12V, G12D, G13D, @Mutation$, L19F, K117N, A146T and R164Q
85	To compare the transformation potential of the K-Ras mutants, therefore, NIH3T3 cells were transiently transfected with plasmids expressing wt @Gene$ and the K-Ras mutations G12V, G12D, G13D, Q61H, @Mutation$, K117N, A146T and R164Q
86	To compare the transformation potential of the K-Ras mutants, therefore, NIH3T3 cells were transiently transfected with plasmids expressing wt @Gene$ and the K-Ras mutations G12V, G12D, G13D, Q61H, L19F, @Mutation$, A146T and R164Q
87	To compare the transformation potential of the K-Ras mutants, therefore, NIH3T3 cells were transiently transfected with plasmids expressing wt @Gene$ and the K-Ras mutations G12V, G12D, G13D, Q61H, L19F, K117N, @Mutation$ and R164Q
88	To compare the transformation potential of the K-Ras mutants, therefore, NIH3T3 cells were transiently transfected with plasmids expressing wt @Gene$ and the K-Ras mutations G12V, G12D, G13D, Q61H, L19F, K117N, A146T and @Mutation$
89	To compare the transformation potential of the K-Ras mutants, therefore, NIH3T3 cells were transiently transfected with plasmids expressing wt K-Ras and the @Gene$ mutations @Mutation$, G12D, G13D, Q61H, L19F, K117N, A146T and R164Q
90	To compare the transformation potential of the K-Ras mutants, therefore, NIH3T3 cells were transiently transfected with plasmids expressing wt K-Ras and the @Gene$ mutations G12V, @Mutation$, G13D, Q61H, L19F, K117N, A146T and R164Q
91	To compare the transformation potential of the K-Ras mutants, therefore, NIH3T3 cells were transiently transfected with plasmids expressing wt K-Ras and the @Gene$ mutations G12V, G12D, @Mutation$, Q61H, L19F, K117N, A146T and R164Q
92	To compare the transformation potential of the K-Ras mutants, therefore, NIH3T3 cells were transiently transfected with plasmids expressing wt K-Ras and the @Gene$ mutations G12V, G12D, G13D, @Mutation$, L19F, K117N, A146T and R164Q
93	To compare the transformation potential of the K-Ras mutants, therefore, NIH3T3 cells were transiently transfected with plasmids expressing wt K-Ras and the @Gene$ mutations G12V, G12D, G13D, Q61H, @Mutation$, K117N, A146T and R164Q
94	To compare the transformation potential of the K-Ras mutants, therefore, NIH3T3 cells were transiently transfected with plasmids expressing wt K-Ras and the @Gene$ mutations G12V, G12D, G13D, Q61H, L19F, @Mutation$, A146T and R164Q
95	To compare the transformation potential of the K-Ras mutants, therefore, NIH3T3 cells were transiently transfected with plasmids expressing wt K-Ras and the @Gene$ mutations G12V, G12D, G13D, Q61H, L19F, K117N, @Mutation$ and R164Q
96	To compare the transformation potential of the K-Ras mutants, therefore, NIH3T3 cells were transiently transfected with plasmids expressing wt K-Ras and the @Gene$ mutations G12V, G12D, G13D, Q61H, L19F, K117N, A146T and @Mutation$
97	Figure 4 illustrates the results of our analysis where, consistent with our focus formation experiments, the @Gene$ @Mutation$ and L19F, K117N and A146T mutations are clearly in the active GTP-bound conformation
98	Figure 4 illustrates the results of our analysis where, consistent with our focus formation experiments, the @Gene$ G12V and @Mutation$, K117N and A146T mutations are clearly in the active GTP-bound conformation
99	Figure 4 illustrates the results of our analysis where, consistent with our focus formation experiments, the @Gene$ G12V and L19F, @Mutation$ and A146T mutations are clearly in the active GTP-bound conformation
100	Figure 4 illustrates the results of our analysis where, consistent with our focus formation experiments, the @Gene$ G12V and L19F, K117N and @Mutation$ mutations are clearly in the active GTP-bound conformation
101	In contrast, the @Mutation$ mutation, like wt @Gene$, was not GTP-bound.
102	It is interesting to note that the codon 12 mutants were most similar to wt @Gene$, whereas the @Mutation$ and A146T mutants clustered with the activating codon 13 and codon 61 hotspot mutants
103	It is interesting to note that the codon 12 mutants were most similar to wt @Gene$, whereas the K117N and @Mutation$ mutants clustered with the activating codon 13 and codon 61 hotspot mutants
104	The presence of @Mutation$ in cluster 2, rather than in cluster 1 with wt @Gene$ was therefore initially surprising, but suggests that the R164Q mutation also has an 'activating' phenotype, albeit attenuated relative to the other mutations studied.
105	The presence of R164Q in cluster 2, rather than in cluster 1 with wt @Gene$ was therefore initially surprising, but suggests that the @Mutation$ mutation also has an 'activating' phenotype, albeit attenuated relative to the other mutations studied.
106	However, there were examples of genes that were induced by all of the mutants studied, including the protein tyrosine phosphatase @Gene$ and the Rho GTPase activating protein Arhgap6, and multiple examples of genes induced or repressed by all of the mutants with the exception of @Mutation$
107	However, there were examples of genes that were induced by all of the mutants studied, including the protein tyrosine phosphatase Ptpre and the Rho GTPase activating protein @Gene$, and multiple examples of genes induced or repressed by all of the mutants with the exception of @Mutation$
108	RFLP analysis of B-@Gene$ @Mutation$ mutation
109	The B-@Gene$ @Mutation$ mutation was detected using a novel RFLP assay, where the presence of the mutation destroyed a recognition site for the restriction enzyme TspRI
110	Samples without the @Gene$ @Mutation$ mutation were digested to produce bands of 124, 78 and 22 bp, whereas samples homozygous for the V599E mutation produced bands of 202 and 22 bp
111	Samples without the @Gene$ V599E mutation were digested to produce bands of 124, 78 and 22 bp, whereas samples homozygous for the @Mutation$ mutation produced bands of 202 and 22 bp
112	Mutation analysis in Costello syndrome: functional and structural characterization of the @Gene$ @Mutation$ mutation
113	(B) The transforming potential of @Mutation$, K117N, A146T and R164Q mutations were compared with the hotspot mutation G12V and wt @Gene$
114	(B) The transforming potential of L19F, @Mutation$, A146T and R164Q mutations were compared with the hotspot mutation G12V and wt @Gene$
115	(B) The transforming potential of L19F, K117N, @Mutation$ and R164Q mutations were compared with the hotspot mutation G12V and wt @Gene$
116	(B) The transforming potential of L19F, K117N, A146T and @Mutation$ mutations were compared with the hotspot mutation G12V and wt @Gene$
117	(B) The transforming potential of L19F, K117N, A146T and R164Q mutations were compared with the hotspot mutation @Mutation$ and wt @Gene$
118	The @Gene$ @Mutation$ construct was included as a positive control for K-Ras protein in the active GTP-bound conformation.
119	The K-Ras @Mutation$ construct was included as a positive control for @Gene$ protein in the active GTP-bound conformation.
120	The mitotic @Mutation$ kinase @Gene$/AIK is regulated by phosphorylation and degradation
121	The mitotic @Mutation$ kinase Aurora2/@Gene$ is regulated by phosphorylation and degradation
122	Following a pilot study in Italy and Spain, analysis of carriers (n = 11,609) collected through 24 study groups participating in the Consortium of Investigators of Modifiers of @Gene$ (CIMBA) detected significant modification of breast cancer risk by HMMR @Mutation$ variant among BRCA1, but not BRCA2, mutation carriers: BRCA1 mutation carriers n = 7,584, Cox proportional-hazards regression model, hazard ratio (HR) = 1.08 (95% confidence interval (CI) 1.02-1.13), ptrend = 0.004 (p 2df = 0.014), in the same direction as originally detected in Ashkenazi Jewish populations; BRCA2 mutation carriers n = 3,965, HR = 1.03 (95% CI 0.96-1.10), ptrend = 0.42 (p 2df = 0.67)
123	Following a pilot study in Italy and Spain, analysis of carriers (n = 11,609) collected through 24 study groups participating in the Consortium of Investigators of Modifiers of BRCA1/2 (CIMBA) detected significant modification of breast cancer risk by @Gene$ @Mutation$ variant among BRCA1, but not BRCA2, mutation carriers: BRCA1 mutation carriers n = 7,584, Cox proportional-hazards regression model, hazard ratio (HR) = 1.08 (95% confidence interval (CI) 1.02-1.13), ptrend = 0.004 (p 2df = 0.014), in the same direction as originally detected in Ashkenazi Jewish populations; BRCA2 mutation carriers n = 3,965, HR = 1.03 (95% CI 0.96-1.10), ptrend = 0.42 (p 2df = 0.67)
124	Following a pilot study in Italy and Spain, analysis of carriers (n = 11,609) collected through 24 study groups participating in the Consortium of Investigators of Modifiers of BRCA1/2 (CIMBA) detected significant modification of breast cancer risk by HMMR @Mutation$ variant among @Gene$, but not BRCA2, mutation carriers: BRCA1 mutation carriers n = 7,584, Cox proportional-hazards regression model, hazard ratio (HR) = 1.08 (95% confidence interval (CI) 1.02-1.13), ptrend = 0.004 (p 2df = 0.014), in the same direction as originally detected in Ashkenazi Jewish populations; BRCA2 mutation carriers n = 3,965, HR = 1.03 (95% CI 0.96-1.10), ptrend = 0.42 (p 2df = 0.67)
125	Following a pilot study in Italy and Spain, analysis of carriers (n = 11,609) collected through 24 study groups participating in the Consortium of Investigators of Modifiers of BRCA1/2 (CIMBA) detected significant modification of breast cancer risk by HMMR @Mutation$ variant among BRCA1, but not @Gene$, mutation carriers: BRCA1 mutation carriers n = 7,584, Cox proportional-hazards regression model, hazard ratio (HR) = 1.08 (95% confidence interval (CI) 1.02-1.13), ptrend = 0.004 (p 2df = 0.014), in the same direction as originally detected in Ashkenazi Jewish populations; BRCA2 mutation carriers n = 3,965, HR = 1.03 (95% CI 0.96-1.10), ptrend = 0.42 (p 2df = 0.67)
126	Following a pilot study in Italy and Spain, analysis of carriers (n = 11,609) collected through 24 study groups participating in the Consortium of Investigators of Modifiers of BRCA1/2 (CIMBA) detected significant modification of breast cancer risk by HMMR @Mutation$ variant among BRCA1, but not BRCA2, mutation carriers: @Gene$ mutation carriers n = 7,584, Cox proportional-hazards regression model, hazard ratio (HR) = 1.08 (95% confidence interval (CI) 1.02-1.13), ptrend = 0.004 (p 2df = 0.014), in the same direction as originally detected in Ashkenazi Jewish populations; BRCA2 mutation carriers n = 3,965, HR = 1.03 (95% CI 0.96-1.10), ptrend = 0.42 (p 2df = 0.67)
127	Following a pilot study in Italy and Spain, analysis of carriers (n = 11,609) collected through 24 study groups participating in the Consortium of Investigators of Modifiers of BRCA1/2 (CIMBA) detected significant modification of breast cancer risk by HMMR @Mutation$ variant among BRCA1, but not BRCA2, mutation carriers: BRCA1 mutation carriers n = 7,584, @Gene$ proportional-hazards regression model, hazard ratio (HR) = 1.08 (95% confidence interval (CI) 1.02-1.13), ptrend = 0.004 (p 2df = 0.014), in the same direction as originally detected in Ashkenazi Jewish populations; BRCA2 mutation carriers n = 3,965, HR = 1.03 (95% CI 0.96-1.10), ptrend = 0.42 (p 2df = 0.67)
128	Following a pilot study in Italy and Spain, analysis of carriers (n = 11,609) collected through 24 study groups participating in the Consortium of Investigators of Modifiers of BRCA1/2 (CIMBA) detected significant modification of breast cancer risk by HMMR @Mutation$ variant among BRCA1, but not BRCA2, mutation carriers: BRCA1 mutation carriers n = 7,584, Cox proportional-hazards regression model, hazard ratio (HR) = 1.08 (95% confidence interval (CI) 1.02-1.13), ptrend = 0.004 (p 2df = 0.014), in the same direction as originally detected in Ashkenazi Jewish populations; @Gene$ mutation carriers n = 3,965, HR = 1.03 (95% CI 0.96-1.10), ptrend = 0.42 (p 2df = 0.67)
129	Effect of @Gene$ @Mutation$ variation on breast cancer risk among BRCA1 and BRCA2 mutation carriers.
130	Effect of HMMR @Mutation$ variation on breast cancer risk among @Gene$ and BRCA2 mutation carriers.
131	Effect of HMMR @Mutation$ variation on breast cancer risk among BRCA1 and @Gene$ mutation carriers.
132	Forrest plots show HRs and 95% CIs of the additive model (@Mutation$ C allele) for all participating centers ordered by sample size (n>30) of @Gene$ mutation carriers (left panel, wHR per study center are shown in Table S2; right panel, effect on BRCA2 mutation carriers)
133	Forrest plots show HRs and 95% CIs of the additive model (@Mutation$ C allele) for all participating centers ordered by sample size (n>30) of BRCA1 mutation carriers (left panel, wHR per study center are shown in Table S2; right panel, effect on @Gene$ mutation carriers)
134	Analysis of public gene expression datasets suggests that the @Mutation$ risk allele is associated with @Gene$ germline over-expression (see also Table S3)
135	Since @Mutation$ is at the fourth base position of @Gene$ exon 5, we evaluated the potential alteration of the splicing pattern of this exon or the ratio of the alternative exon 4
136	In data provided by several CIMBA groups (Text S1), no @Gene$-positive tumors were observed among rare @Mutation$ homozygotes in BRCA1 mutation carriers (p interaction = 0.006), whereas this bias was not observed in BRCA2 mutation carriers (p interaction = 0.95) (Table S4)
137	In data provided by several CIMBA groups (Text S1), no ER-positive tumors were observed among rare @Mutation$ homozygotes in @Gene$ mutation carriers (p interaction = 0.006), whereas this bias was not observed in BRCA2 mutation carriers (p interaction = 0.95) (Table S4)
138	In data provided by several CIMBA groups (Text S1), no ER-positive tumors were observed among rare @Mutation$ homozygotes in BRCA1 mutation carriers (p interaction = 0.006), whereas this bias was not observed in @Gene$ mutation carriers (p interaction = 0.95) (Table S4)
139	That is, despite the expected differences in the frequency of tumor types between the two sets of carriers, heterogeneity was observed in the distribution of @Mutation$ genotypes in @Gene$, but not BRCA2, mutation carriers
140	That is, despite the expected differences in the frequency of tumor types between the two sets of carriers, heterogeneity was observed in the distribution of @Mutation$ genotypes in BRCA1, but not @Gene$, mutation carriers
141	Importantly, both proteasome inhibition and @Gene$ depletion increased the abundance of RHAMM (Figure @Mutation$), which is also consistent with observed RHAMM over-expression in breast cancer cell lines derived from BRCA1 mutation carriers
142	Importantly, both proteasome inhibition and BRCA1 depletion increased the abundance of @Gene$ (Figure @Mutation$), which is also consistent with observed RHAMM over-expression in breast cancer cell lines derived from BRCA1 mutation carriers
143	Importantly, both proteasome inhibition and BRCA1 depletion increased the abundance of RHAMM (Figure @Mutation$), which is also consistent with observed @Gene$ over-expression in breast cancer cell lines derived from BRCA1 mutation carriers
144	Importantly, both proteasome inhibition and BRCA1 depletion increased the abundance of RHAMM (Figure @Mutation$), which is also consistent with observed RHAMM over-expression in breast cancer cell lines derived from @Gene$ mutation carriers
145	@Gene$ depletion, however, did not alter AURKA levels (Figure @Mutation$)
146	BRCA1 depletion, however, did not alter @Gene$ levels (Figure @Mutation$)
147	In contrast to single depletions, simultaneous reduction of @Gene$ and RHAMM levels recovered normal acini formation (Figure @Mutation$), possibly implying a negative regulatory relationship between RHAMM abundance and AURKA activity
148	In contrast to single depletions, simultaneous reduction of AURKA and @Gene$ levels recovered normal acini formation (Figure @Mutation$), possibly implying a negative regulatory relationship between RHAMM abundance and AURKA activity
149	In contrast to single depletions, simultaneous reduction of AURKA and RHAMM levels recovered normal acini formation (Figure @Mutation$), possibly implying a negative regulatory relationship between @Gene$ abundance and AURKA activity
150	In contrast to single depletions, simultaneous reduction of AURKA and RHAMM levels recovered normal acini formation (Figure @Mutation$), possibly implying a negative regulatory relationship between RHAMM abundance and @Gene$ activity
151	Consistently, @Gene$ depletion reduced RHAMM levels (Figure S7C), while simultaneous depletion of AURKA and BRCA1 recovered RHAMM to control levels (Figure @Mutation$)
152	Consistently, AURKA depletion reduced @Gene$ levels (Figure S7C), while simultaneous depletion of AURKA and BRCA1 recovered RHAMM to control levels (Figure @Mutation$)
153	Consistently, AURKA depletion reduced RHAMM levels (Figure S7C), while simultaneous depletion of @Gene$ and BRCA1 recovered RHAMM to control levels (Figure @Mutation$)
154	Consistently, AURKA depletion reduced RHAMM levels (Figure S7C), while simultaneous depletion of AURKA and @Gene$ recovered RHAMM to control levels (Figure @Mutation$)
155	Consistently, AURKA depletion reduced RHAMM levels (Figure S7C), while simultaneous depletion of AURKA and BRCA1 recovered @Gene$ to control levels (Figure @Mutation$)
156	In MCF10A cells, @Gene$ abundance and activity determined total RHAMM as well as pT703-RHAMM levels (Figure @Mutation$)
157	In MCF10A cells, AURKA abundance and activity determined total @Gene$ as well as pT703-RHAMM levels (Figure @Mutation$)
158	In MCF10A cells, AURKA abundance and activity determined total RHAMM as well as pT703-@Gene$ levels (Figure @Mutation$)
159	This model is consistent with reduced expression of @Gene$, TPX2, and HMMR, but to a lesser extent BRCA1, with polarization and growth arrest of nonmalignant mammary epithelial cells, as measured by gene expression profiling (Figure @Mutation$)
160	This model is consistent with reduced expression of AURKA, @Gene$, and HMMR, but to a lesser extent BRCA1, with polarization and growth arrest of nonmalignant mammary epithelial cells, as measured by gene expression profiling (Figure @Mutation$)
161	This model is consistent with reduced expression of AURKA, TPX2, and @Gene$, but to a lesser extent BRCA1, with polarization and growth arrest of nonmalignant mammary epithelial cells, as measured by gene expression profiling (Figure @Mutation$)
162	This model is consistent with reduced expression of AURKA, TPX2, and HMMR, but to a lesser extent @Gene$, with polarization and growth arrest of nonmalignant mammary epithelial cells, as measured by gene expression profiling (Figure @Mutation$)
163	According to the model and as stated above, analysis of public gene expression datasets suggests that the @Mutation$ risk allele is associated with @Gene$ germline over-expression (Table S3)
164	As the potential splicing alteration by @Mutation$ might be tissue specific and @Gene$-R92 was used in the over-expression assays, further work may be warranted to define the causal mutation(s) and the alteration of RHAMM function and/or expression level according to the depicted model.
165	As the potential splicing alteration by @Mutation$ might be tissue specific and RHAMM-R92 was used in the over-expression assays, further work may be warranted to define the causal mutation(s) and the alteration of @Gene$ function and/or expression level according to the depicted model.
166	As the potential splicing alteration by rs299284 might be tissue specific and @Gene$-@Mutation$ was used in the over-expression assays, further work may be warranted to define the causal mutation(s) and the alteration of RHAMM function and/or expression level according to the depicted model.
167	As the potential splicing alteration by rs299284 might be tissue specific and RHAMM-@Mutation$ was used in the over-expression assays, further work may be warranted to define the causal mutation(s) and the alteration of @Gene$ function and/or expression level according to the depicted model.
168	In preparation for mitotic spindle assembly, @Gene$ promotes centrosome-dependent microtubule assembly by suppressing BRCA1-dependent ubiquitination, which involves BRCA1 phosphorylation at @Mutation$
169	In preparation for mitotic spindle assembly, AURKA promotes centrosome-dependent microtubule assembly by suppressing @Gene$-dependent ubiquitination, which involves BRCA1 phosphorylation at @Mutation$
170	In preparation for mitotic spindle assembly, AURKA promotes centrosome-dependent microtubule assembly by suppressing BRCA1-dependent ubiquitination, which involves @Gene$ phosphorylation at @Mutation$
171	Accordingly, @Gene$ depletion increases the clonogenic potential of mammary epithelia, while a BRCA1 @Mutation$ mutant alters embryonic stem cell differentiation
172	Accordingly, BRCA1 depletion increases the clonogenic potential of mammary epithelia, while a @Gene$ @Mutation$ mutant alters embryonic stem cell differentiation
173	In order to reconstitute HCC1937 cells with wild-type @Gene$, the corresponding full-length open-reading frame was cloned into a retroviral vector @Mutation$ and transduced
174	"This work was funded by the Spanish Ministries of Health, and Science ane Innovation (CB07/02/2005; @Gene$ 08/1120, 08/1359, 08/1635, and 09/02483; RTICCC RD06/0020/1060 and RD06/0020/0028; Transversal Action Against Cancer; the Spanish Biomedical Research Centre Networks for Epidemiology and Public Health, and Rare Diseases; and the ""Ramon y Cajal"" Young Investigator Program), the Spanish National Society of Medical Oncology (2010), the Spanish Association Against Cancer (AECC 2010), the AGAUR Catalan Government Agency (2009SGR1489 and 2009SGR293; and the Beatriu Pinos Postdoctoral Program), the Ramon Areces Foundation (XV), the ""Roses Contra el Cancer"" Foundation, the Michael Cuccione Foundation for Childhood Cancer Research, Cancer Research-UK (C490/A10119, @Mutation$, C1287/A10118, C5047/A8385, and C8197/A10123), the National Institute for Health Research (UK), the Association for International Cancer Research (AICR-07-0454), the Ligue National Contre le Cancer (France), the Association ""Le cancer du sein, parlons-en!"", the Dutch Cancer Society (NKI 1998-1854, 2004-3088, and 2007-3756), the Fondazione Italiana per la Ricerca sul Cancro (""Hereditary Tumors""), the Associazione Italiana per la Ricerca sul Cancro (4017), the Italian Ministero della Salute (RFPS-2006-3-340203 and ""Progetto Tumori Femminili""), the Italian Ministero dell'Universita' e Ricerca (RBLAO3-BETH), the Fondazione IRCCS Istituto Nazionale Tumori (INT ""5x1000""), the Fondazione Cassa di Risparmio di Pisa (Istituto Toscano Tumori), the National Breast Cancer Foundation (Australia), the Australian National Health and Medical Research Council (145684, 288704, and 454508), the Queensland Cancer Fund, the Cancer Councils of New South Wales, Victoria, Tasmania, and South Australia, the Cancer Foundation of Western Australia, the German Cancer Aid (107054), the Center for Molecular Medicine Cologne (TV93), the National Cancer Institute (USA; CA128978 and CA122340), National Institutes of Health (RFA-CA-06-503, BCFR U01 CA69398, CA69417, CA69446, CA69467, CA69631, and CA69638), the Research Triangle Institute Informatics Support Center (RFP N02PC45022-46), the Specialized Program of Research Excellence (SPORE P50 CA83638 and CA113916), the Department of Defense Breast Cancer Research Program (05/0612), the Eileen Stein Jacoby Fund, the Breast Cancer Research Foundation, the Marianne and Robert MacDonald Foundation, the Komen Foundation, the Helsinki University Central Hospital Research Fund, the Academy of Finland (110663), the Finnish Cancer Society, the Sigrid Juselius Foundation, and the EU FP7 (223175, HEALTH-F2-2009-223175)"
175	The @Mutation$ mutation (c.68_69delAG) in the @Gene$ gene triggers translation reinitiation at a downstream AUG codon.
176	The 185delAG mutation (@Mutation$) in the @Gene$ gene triggers translation reinitiation at a downstream AUG codon.
177	Inconsistent association between the @Gene$ @Mutation$ genetic polymorphism and breast cancer risk.
